2025-03-10
1. Summary of the Week
In the first week of March, 12 agreements were signed globally, including 3 from China’s biotech industry.
Neuro3 and Nhwa Pharmaceutical entered into an investment and option deal for the preclinical asset KCNQ2 activator 1, while Insilico Medicine and Tenacia Biotechnology signed a cooperation agreement for another preclinical asset. Delova Biotech and Sino Biopharmaceutical signed a cooperation deal for the NDA Filed asset, QP001 (meloxicam).
Overall, 9 deals were signed worldwide. The largest licensing agreement of the week was between Gubra and AbbVie for the Phase I asset GUB014295, valued at $2.225 billion, with an upfront payment of $350 million.
2025年3月1日-7日，全球医药市场共签署了12项资产授权和合作协议。中国市场共达成3项交易，均为国内交易。
本周的三项国内交易分别是恩华药业入股三晟医药，并获得部分在研药品合作的优先谈判权；英矽智能与元羿生物达成合作，以生成式AI赋能中枢神经系统药物研发；中国生物制药引进清普生物NDA阶段资产QP001中国大陆地区权益。
国际市场上，本周共签署了9项资产授权和合作协议。最大的一笔交易是AbbVie与Gubra达成的许可协议，共同开发临床一期资产GUB014295，首付款3.5亿美元，总金额22亿美元。
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of 2024
5. 2019-2024 China Innovative Drug Licensing Transactions
About YAFO CAPITAL
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
ACCESS CHINA
Event Name:
2025-06 ACCESS CHINA @ Boston Forum, Virtual & Boston
BioToChina.org 